Literature DB >> 19837290

Influenza vaccines.

A H Ellebedy1, R J Webby.   

Abstract

Influenza A viruses pose a substantial threat to the human population whether by purposeful manipulation and release or by the natural process of interspecies transmissions from animal reservoirs. The challenge with preparing for these events with vaccination strategies is that the best forms of protective immunity target the most variable of the viral proteins, hemagglutinin. Add to this even just the natural extent of variation in this protein and the challenges to vaccinologists become great. Progress must be made in the area of streamlining the conventional vaccine approaches, but also in further defining and testing more conserved protective antigens. Within the context of biodefense, the issue will be to reach a balance where some of the diversity of influenza viruses can be encompassed within a vaccine while maintaining an acceptable level of efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837290      PMCID: PMC2900784          DOI: 10.1016/j.vaccine.2009.08.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

Review 1.  Vaccines for preventing influenza in healthy adults.

Authors:  V Demicheli; D Rivetti; J J Deeks; T O Jefferson
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  A history of influenza.

Authors:  C W Potter
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

3.  Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity.

Authors:  T Watanabe; S Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Authors:  Timo Vesikari; Michele Pellegrini; Aino Karvonen; Nicola Groth; Astrid Borkowski; Derek T O'Hagan; Audino Podda
Journal:  Pediatr Infect Dis J       Date:  2009-07       Impact factor: 2.129

5.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Authors:  J Talon; M Salvatore; R E O'Neill; Y Nakaya; H Zheng; T Muster; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 8.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Authors:  J J Skehel; D C Wiley
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 9.  Live attenuated vaccines against influenza; an historical review.

Authors:  M D Wareing; G A Tannock
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

10.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Authors:  Suzanne L Epstein; Terrence M Tumpey; Julia A Misplon; Chia-Yun Lo; Lynn A Cooper; Kanta Subbarao; Mary Renshaw; Suryaprakash Sambhara; Jacqueline M Katz
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more
  54 in total

1.  The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity.

Authors:  Katherine A Richards; Francisco A Chaves; Andrea J Sant
Journal:  Immunology       Date:  2011-03-29       Impact factor: 7.397

2.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

4.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

Review 6.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

7.  How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.

Authors:  Andreas Handel; Victoria Akin; Sergei S Pilyugin; Veronika Zarnitsyna; Rustom Antia
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

Review 8.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

Review 10.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.